EU Trade Group Backs FDA's $300M Generics Fees Plan

Law360, New York (September 9, 2011, 6:03 PM EDT) -- A European chemical trade group on Friday became the last of three major industry groups to ratify a proposal that calls for generic-drug makers to pay $299 million in annual fees to the U.S. Food and Drug Administration.

European Fine Chemicals Group ratified the proposal for a new program will help ease a crippling backlog in FDA approval for generic medicines by enabling the agency to hire more staff, beef up plant inspections and tackle a backlog of thousands of drug applications, the agency said.

The proposal cleared two American trade organizations,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.